Redeye provides a research update following the Q4 report published by Initiator Pharma earlier today. The company continues to operate at surprisingly low cash burn levels, showing promise for the financial runway ahead. Having actively engaged in key business development events; the main focus of the company has been on business development efforts. We repeat that the full priority for the coming period will be to find a licensing partner for pudafensine.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/